Craig-Hallum analyst Alex Novak lowered the firm’s price target on Accelerate Diagnostics (AXDX) to $2 from $5 and keeps a Hold rating on the shares. The firm notes Q4 was another challenged quarter for the company. Accelerate has still not seen any of the Becton Dickinson (BDX) partnership progress convert into meaningful revenue, Craig-Hallum adds.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXDX: